NVS’ internal NASH drug candidates (which could potentially be combined with Enricasan) are FXR agonists—the same class as ICPT’s OCA and ENTA’s EDP-305 (among others).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.